Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00737594 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension
A Phase 2 study, sponsored by Sucampo Pharma Americas.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00737594 is a Phase 2 study that was terminated before completion, run by Sucampo Pharma Americas. The registered enrollment target is 9 participants.
The verdict
NCT00737594, a Phase 2 study, was terminated before completion, sponsored by Sucampo Pharma Americas.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine the efficacy and safety of cobiprostone (at two dose levels) as compared to placebo for lowering portal hypertension.
Interventions
- DRUG Placebo
- DRUG Cobiprostone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00737594
The ClinicalTrials.gov registry entry for NCT00737594 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sucampo Pharma Americas, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00737594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00737594 about?
NCT00737594 is a clinical study titled "Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension". The primary purpose of this study is to determine the efficacy and safety of cobiprostone (at two dose levels) as compared to placebo for lowering portal hypertension.
What is the current status of trial NCT00737594?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2008-07. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00737594?
The interventions under investigation include: Placebo (DRUG), Cobiprostone (DRUG).
Who is sponsoring clinical trial NCT00737594?
This trial is sponsored by Sucampo Pharma Americas, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.